NCT05198362View on ClinicalTrials.gov

Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 28, 2021

Primary Completion Date

December 9, 2022

Study Completion Date

December 9, 2022

Conditions

Prader-Willi Syndrome

Interventions

OTHER

Placebo

Inactive comparator

DRUG

Tesomet

Fixed-dose combination

Trial Locations (1)

48912

Sparrow Clinical Research Institute, Lansing

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Saniona

INDUSTRY